Publications

Role of Neutrophil Lymphocyte Ratio [NLR] as a biomarker of frailty and predictor of survival among older adults with Multiple Myeloma →

Giri, S, Costa, LJ, Godby, KN, Bhatia, S, Williams, G, Olszewski, A

December 2020

Abstract

American Society of Hematology Annual Meeting

Redefining the prognostic significance of t(11,14) multiple myeloma →

Giri, S, Costa, LJ, Godby, KN, Bhatia, S, Williams, G

December 2020

Abstract

American Society of Hematology Annual Meeting

Multiple myeloma in the very old: disease characteristics, treatment patterns and outcomes in the real world →

Giri, S, Costa, LJ, Godby, KN, Bhatia, S, Williams, G

December 2020

Abstract

American Society of Hematology Annual Meeting

Real-world use of maintenance therapy and associated outcomes following autologous stem cell transplant in US patients with newly diagnosed multiple myeloma →

Ammann, EM, Lam, A, Fu, Z, Kampfenkel, T, Sharma, M, Tang, W, Lee, C, Kaila, S, He, J

December 2020

Abstract

American Society of Hematology Annual Meeting

Identification and reporting of cell of origin, double-/triple-hit and double expressor lymphoma in a real-world cohort of diffuse large B-cell lymphoma patients →

Yang, F, Abraham, A, Zhang, J, Xiao, Y, Hammer, R, Prime, M

December 2020

Abstract

American Society of Hematology Annual Meeting

A clinical practice comparison of patients with CLL/SLL with and without del(17p) receiving first-line treatment with ibrutinib →

Hedrick, E, Mato, A, Sharman, J, Tang, B, Azmi, S, Pinilla-Ibarz, J, Yang, K, Stern, J, Huang, J

December 2020

Abstract

American Society of Hematology Annual Meeting

Use of venetoclax and hypomethylating agents (HMA) in newly diagnosed acute myeloid leukemia (AML) in the United States – real world (RW) response, treatment duration, dose and schedule modifications →

Donnellan, W, Xu, T, Ma, E, Jin, J, Montez, M, Choi, M, Ku, G, Rajeswaran, A, Flahavan, EM

December 2020

Abstract

American Society of Hematology Annual Meeting

Treatment patterns and outcomes of patients with newly diagnosed acute myeloid leukemia (AML) treated with hypomethylating agents (HMA) in the United States →

Pardee, T, Oschwald, J, Ma, E, Xu, T, Montez, M, Hong, W, Choi, M, Flahavan, EM

December 2020

Abstract

American Society of Hematology Annual Meeting

Real world data (RWD) treatment (tx) patterns and sequencing of patients with multiple myeloma (MM) →

Gershon, A, Liu, Y, James, S, Williamson, M, Hong, W, Sarsour, K

December 2020

Abstract

American Society of Hematology Annual Meeting

Treatment patterns and outcomes of multiple myeloma (MM) with chromosome translocation (11,14) in United States routine clinical practice →

Atrash, S, Flahavan, EM, Xu, T, Ma, E, Karve, S, Hong, W, Jirau-Lucca, G, Nixon, M, Ailawadhi, S

December 2020

Abstract

American Society of Hematology Annual Meeting

Real-world outcomes of patients with Diffuse Large B-Cell Lymphoma receiving second line therapy in the United States →

Sawas, A, Lau, C, Thomson, M, Maignan, K

December 2020

Abstract

American Society of Hematology Annual Meeting

Flatiron-authored

Progression free survival of relapsed or refractory multiple myeloma (RRMM) after failure of three prior lines of therapy in United States real-world practice →

Kim, C, Braunlin, M, Belani, R, Wheeling, JT

December 2020

Abstract

American Society of Hematology Annual Meeting

Real-world IgG testing frequency and characteristics associated with hypogammaglobulinemia after anti-CD20 exposure in patients with chronic lymphocytic leukemia →

Hooley, IJ, Maignan, K, Jacob, A, Medina, A, Benderoff, L, Chen, R, Huntington, SF

December 2020

Abstract

American Society of Hematology Annual Meeting

Flatiron-authored

Real-world data as an evidence source in nuclear medicine →

Bourla, AB, Hermann, K

November 2020

Manuscript

Journal of Nuclear Medicine

Flatiron-authored

Understanding the impact of assessment frequency on the study of adverse effects using oncology electronic health records →

Liang, Q, Zhang, Q, Rosic, A, Bowser, B, Tharani, S, Brake, SD, Magee, K, Parrinello, CM, Baxi, SS

November 2020

Abstract

EU ISPOR

Flatiron-authored

Deriving International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk categories using oncology electronic health records →

Mathur, R, Barata, P, Tan, K, Pini, M, Magee, K, Baxi, SS

November 2020

Abstract

EU ISPOR

Flatiron-authored

Prevalence of high tumor mutational burden and association with survival in patients with less common solid tumors →

Shao, C, Li, G, Huang, L, Pruitt, SK, Castellanos, EH, Frampton, GM, Carson, KR, Snow, T, Singal, G, Fabrizio, D, Alexander, BM, Jin, FJ, Zhou, W

October 2020

Manuscript

JAMA Open

Flatiron-authored

Comparative effectiveness of trastuzumab emtansine versus lapatinib plus capecitabine for HER2+ metastatic breast cancer →

Ramagopalan, S, Pisoni, R, Zenin, A, Rathore, LS, Ray, J, Sammon, C

October 2020

Manuscript

Journal of Comparative Effectiveness Research

Supporting optimal; value-based; and sustainable cancer care delivery →

McAneny, B, Schwartzberg, L, Koh, W, Arrowsmith, E, Fugaro, A, Haydell, T, Hesketh, PJ, Pudusseri, A, Richey, S, Zarwan, C, Stein, R

October 2020

Manuscript

Journal of Clinical Pathways

Flatiron-authored

First-line immunotherapy versus targeted therapy in patients with BRAF-mutant advanced melanoma: a real-world analysis →

Pavlick, AC, Zhao, R, Lee, C-H, Ritchings, C, Rao, S

October 2020

Manuscript

Future Oncology

Using electronic health record data to identify comparator populations for comparative effectiveness research →

Ramsey, SD, Adamson, BJ, Wang, X, Bargo, D, Baxi, SS, Ghosh, S, Meropol, NJ

October 2020

Manuscript

Journal of Medical Economics

Flatiron-authored

Real-world outcomes associated with liposomal irinotecan dose reductions in metastatic pancreatic ductal adenocarcinoma →

Abushahin, LI, Cockrum, P, Surinach, A, Belanger, B

October 2020

Manuscript

Future Oncology

Considerations for use of real-world evidence in oncology: lessons learned from Friends of Cancer Research collaborations →

Baxi, SS, Cohen, AB, Mahoney, N, Rasmussen, E, Tymejczyk, O, Torres, AZ

October 2020

Manuscript

Friends of Cancer Research

Flatiron-authored

Prospective validation of a clinical tool developed with machine learning to identify high-risk patients with cancer and reduce emergency department visits →

Coombs, L, Orlando, A, Adamson, BJS, Griffith, SD, Lakhtakia, S, Rich, A, Shaw, P, Wang, X, Miksad, RA, Mooney, K

October 2020

Abstract

ASCO Quality Care Symposium

Flatiron-authored

Trends in the multiple myeloma treatment landscape and survival: a U.S. analysis using 2011–2019 oncology clinic electronic health record data →

Braunlin, M, Belani, R, Buchanan, J, Wheeling, JT, Kim, C

October 2020

Manuscript

Leukemia and Lymphoma

Association of baseline systemic corticosteroid use with overall survival and time to next treatment in patients receiving immune checkpoint inhibitor therapy in real-world US oncology practice for advanced non-small cell lung cancer, melanoma, or urothelial carcinoma →

Drakaki, A, Dhillon, PK, Wakelee, H, Chui, S, Shim, J, Kent, M, Degaonkar, V, Hoang, T, McNally, V, Luhn, P, Gutzmer, R

October 2020

Manuscript

OncoImmunology

Reducing nihilism in metastatic pancreatic ductal adenocarcinoma: treatment, sequencing, and effects on survival outcomes →

O'Reilly, EM, Cockrum, P, Surinach, A, Wu, Z, Dillon, A, Yu, KH

September 2020

Manuscript

Cancer Medicine

Real-world outcomes among HER2+ metastatic breast cancer patients with brain metastases →

Lindegger, N, Ike, C, Schwartz, NRM, Surinach, A, Liu, Y, Forero-Torres, A, DeBusk, K

September 2020

Abstract

ESMO Annual Congress

Real-world data (RWD) survival analysis of first line (1L) metastatic colorectal cancer (mCRC) patients (pts) with BRAF V600 and non-V600, KRAS G12 and G13, and NRAS mutations →

Gershon, A, Machado, R, Trinh, H, Julian, C, Shi, Z, Zhang, Q, Yan, Y

September 2020

Abstract

ESMO Annual Congress

Applying big data to address the social determinants of health in oncology: proceedings of a workshop →

Meropol, NJ, Adamson, BJS, Miksad, RA

September 2020

Manuscript

Applying Big Data to Address the Social Determinants of Health in Oncology Workshop

Flatiron-authored

STK11 (LKB1) mutations in metastatic NSCLC: prognostic value in the real world →

Shire NJ, Klein, AB, Golozar, A, Collins, JM, Fraeman, KH, Nordstrom, BL, McEwen, R, Hembrough, T, Rizvi, NA

September 2020

Manuscript

PLoS One

A roadmap for developing study endpoints in real-world settings →

Baxi, SS, Koontz, L, Mahoney, N, Torres, AZ, Bourla, AB

August 2020

Manuscript

Duke-Margolis Center for Health Policy

Flatiron-authored

Daratumumab-lenalidomide-dexamethasone vs standard-of-care regimens: Efficacy in transplant-ineligible untreated myeloma →

Durie, BGM, Kumar, S, Usmani, SZ, Nonyane, BAS, Ammann, EM, Lam, A, Kobos, R, Maiese, EM, Facon, T

August 2020

Manuscript

American Journal of Hematology (AJH)

Real-world survival of heavily pretreated patients with refractory HR+, HER2-metastatic breast cancer receiving single-agent chemotherapy-A comparison with MONARCH 1 →

Rugo, HS, Dieras, V, Cortes, J, Patt, D, Wildiers, H, O'Shaughnessy, J, Zamora, E, Yardley, DA, Carter, GC, Sheffield, KM, Li, L, Andre, VAM, Derbyshire, RE, Li, XI, Frenzel, M, Huang, Y, Dickler, MN, Tolaney, SM

August 2020

Manuscript

Breast Cancer Research and Treatment

Analytic considerations for constructing real-world comparator cohorts →

Tan, K, Segal, BD, Bryan, J, Curtis, MD, Nussbaum, NC, Miksad, RA, Samant, MK, Sarkar, S, Torres, AZ

August 2020

Abstract

Joint Statistical Meeting

Flatiron-authored

Retrospective analysis of real-world data to determine clinical outcomes of patients with advanced non-small cell lung cancer following cell-free circulating tumor DNA genomic profiling →

Madison, RW, Schrock, AB, Castellanos, EH, Gregg, JP, Snider, J, Ali, SM, Miller, VA, Singal, G, Alexander, BM, Venstrom, JM, Chung, JH

August 2020

Manuscript

Lung Cancer

Flatiron-authored

An enhanced prognostic score for overall survival of patients with cancer derived from a large real-world cohort →

Becker, T, Weberpals, J, Jegg, AM, So, WV, Fischer, A, Weisser, M, Schmich, F, Rüttinger, D, Bauer-Mehren, A

July 2020

Manuscript

Annals of Oncology

Utilization trends and factors associated with ROS1 testing among patients with advanced non small-cell lung cancer in US community practices →

Wong, WB, Wu, N, Gupta, R, Mansfield, AS

July 2020

Manuscript

The Oncologist

Organ dysfunction in advanced melanoma patients treated with immune checkpoint inhibitors →

Spillane, S, Baxi, SS, Torres, AZ, Lenis, D, Freedman, AN, Mariotto, A

July 2020

Manuscript

The Oncologist

Flatiron-authored

The adoption of immune checkpoint inhibitors and patterns of care at the end of life →

Riaz, F, Gan, G, Li, F, Davidoff, AJ, Adelson, KB, Presley, CJ, Adamson, BJS, Shaw, P, Parikh, RB, Mamtani, R, Gross, CP

July 2020

Manuscript

JCO Oncology Practice

Flatiron-authored

Value of precision medicine in advanced non-small cell lung cancer: Real-world outcomes associated with the use of companion diagnostics →

John, A, Shah, RA, Wong, WB, Schneider, CE, Alexander, M

July 2020

Manuscript

The Oncologist

Patient characteristics, treatment patterns, and outcomes in patients with triple-class-refractory multiple myeloma →

Mehra, M, Vogel, M, Valluri, S, Nair, S, Schecter, J, Slowik, R, Jagannath, S, Weisel, K, Usmani, SZ

June 2020

Abstract

Congress of the European Hematology Association

Real-world treatment patterns and outcomes in patients receiving second-line therapy for advanced/metastatic esophageal squamous cell carcinoma →

Abraham, P, Gricar, J, Zhang, Y, Shankaran, V

June 2020

Manuscript

Advances in Therapy

Association of programmed cell death ligand 1 expression status with receipt of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer →

Leapman, MS, Presley, CJ, Zhu, W, Soulos, PR, Adelson, KB, Miksad, RA, Boffa, DJ, Gross, CP

June 2020

Manuscript

JAMA Open

Flatiron-authored

Evaluating the impact of oncology care model reporting requirements on biomarker testing and treatment →

Castellanos, EH, Orlando, A, Ma, X, Parikh, RB, O'Connell, G, Meropol, NJ, Hamrick, HJ, Adamson, BJS

June 2020

Manuscript

Journal of Oncology Practice

Flatiron-authored

Prior treatment time impacts survival outcomes in metastatic breast cancer →

Rocque, GB, Gilbert, A, Williams, CP, Kenzik, KM, Nakhmani, A, Kandhare, PG, Bhatia, S, Burkard, ME, Azuero, A

June 2020

Manuscript

JCO Clinical Cancer Informatics

Clinical and genomic characteristics of small-cell lung cancer in never-smokers →

Thomas, A, Mian, I, Tlemsani, C, Pongor, L, Takahashi, N, Maignan, K, Snider, J, Li, G, Frampton, GM, Ali, SM, Kim, S, Nichols, S, Rajapakse, V, Guha, U, Sharon, E, Fujimoto, J, Moran, CA, Witstuba, II, Wei, JS, Szabo, E, Torres, AZ, Carson, KR

May 2020

Manuscript

Chest

Flatiron-authored

Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents →

Giri, S, Huntington, SF, Wang, R, Zeidan, AM, Podoltsev, NA, Gore, SD, Ma, X, Gross, CP, Davidoff, AJ, Neparidze, N

May 2020

Manuscript

Blood Advances

Comparative effectiveness of second-line ipilimumab vs. nivolumab in combination with ipilimumab in patients with advanced melanoma who received frontline anti-PD-1 antibodies →

Baron, K, Moser, JC, Patel, P, Grossman, KF, Colonna, SV, Hyngstrom, JR

May 2020

Manuscript

Journal of Oncology Pharmacy Practice

Real-world outcomes in patients with relapsed/refractory diffuse large B-cell lymphoma receiving palliative intent therapies →

Ayers, EC, Margolis, DJ, Landsburg, DJ

May 2020

Manuscript

Clinical Lymphoma; Myeloma; and Leukemia